Late-breaking data to be featured in an oral presentation at the American Association for Cancer Research (AACR) annual meeting on Monday, April 8 and highlighted as part of the official meeting press program
Aims to become a leading global partner for botanical extracts and natural actives in the beauty and personal care market
The company will respond to the Warning Letter within the stipulated timelines
The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD) Prozac Tablets of Eli Lilly
The observations are procedural in nature and will be responded to within the stipulated time
The Product is expected to be the first generic approval on the market
A game changing solution for the pharmaceutical industry
Subscribe To Our Newsletter & Stay Updated